ACHE and early-onset autosomal dominant Alzheimer disease: In early 1990s, when AChE inhibitors started to be developed for the palliative treatment of Alzheimer disease (AD), a related silyl compound, Zifrosilone (Figure 1B) [7] was considered as a promising anti-AD symptomatic drug.